ArticlePain management nursing : official journal of the American Society of Pain Management Nurses2025
Buprenorphine Is Associated With Lower Home Opioid Use and Acute Care Utilization in Sickle Cell Disease.
Article in Pain management nursing : official journal of the American Society of Pain Management Nurses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Qualitative Phenomenological Study of Treatment Options for Patients with SCD and Chronic Pain: Buprenorphine-Naloxone or Full-Agonist Therapy.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionSickle cell disease (SCD) is an inherited genetic disorder affecting an estimated 100,000 people in the United States. The hallmark of SCD is acute and chronic pain, which leads to increased healthcare utilization. Pain in SCD is treated with full opioid agonists with variable effectiveness. There is growing evidence supporting buprenorphine in adults with SCD for pain.
objectivesThe objective of this study was to describe the health outcomes of buprenorphine use in adults with SCD.
methodsThis study was a single-center, retrospective cohort study of all individuals with SCD and chronic pain treated with buprenorphine between November 2020 and January 2024. Descriptive statistics and paired t-tests were used to compare health outcomes before and after treatment.
resultsThirteen inductions were completed, six using telemedicine, two with a diagnosis of opioid use disorder, one individual (7.7%) failed induction and did not continue buprenorphine. Median duration of follow-up was 103 days (range 21-1,497 days). Buprenorphine use was associated with lower annualized rates of emergency department visits (7.2 vs 5.9, -1.3, p < .001), hospital admissions (8.5 vs 5.6, -2.9, p < .001), and treatment center visits (3.0 vs 2.2, -0.9, p < .001), and lower rates of home opioid use (189.3 vs 35.6 morphine milligram equivalent, -153.7, p < .001).
conclusionBuprenorphine induction was successful using telemedicine and for those with opioid use disorder. Buprenorphine was associated with lower opioid use and healthcare utilization in patients with SCD and chronic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.